CONDITIONS TREATeD / ALZHEIMER’S DISEASE
Regenerate. Repair. Restore.
Stem Cells Therapy for Alzheimers Disease and neurodegeneration
WHAT IS STEM CELL THERAPY?
HOW STEM CELL THERAPY WILL HELP?
WHAT SETS US APART?
WHY STEM CELLS TRANSPLANT INSTITUTE?
Neurodegeneration is the progressive loss of structure and/or function of neurons including death. Neurodegenerative diseases include; Alzheimer’s disease, Parkinson’s disease and Huntington’s disease. Alzheimer’s disease (AD) is the most common cause of dementia and is responsible for 60-80 percent of dementia cases. The Stem Cells Transplant Institute recommends the use of mesenchymal stem cells, derived cultured, and expanded from umbilical cord tissue, for the treatment of neurological diseases including Alzheimer’s disease.
Treatment at the Stem Cells Transplant Institute could help improve the symptoms of Alzheimer’s disease including:
- Forgetfulness
- Confusion
- Mood swings
- Distrust in others
- Changes in sleeping habits
- Depression
- Irritability and aggressiveness
- Wandering
- Apathy
- Social withdrawal
What is Alzheimer’s disease?
Dementia is a fatal disease characterized by chronic inflammation and neuronal loss resulting in amnesia, progressive cognitive impairment, and disorientation.
Alzheimer’s disease is the most common form of dementia with more than 5 million people in the United States living with this devastating disease, and it is the 6th leading cause of death, killing more people than prostate cancer and breast cancer combined.1.
The exact cause of Alzheimer’s disease is unknown but there are four key features; 1. Amyloid-beta (Aß) plaques, 2. Neurofibrillary tangles, 3. Neuroinflammation, and 4. Mass neuronal and synaptic loss. Amyloid-beta plaques are sticky clumps of protein fragments that accumulate and attack brain cells, leading to their death. Neurofibrillary tangles are twisted fibers of Tau protein that build up inside the neurons of Alzheimer’s patients damaging neural structures and inhibiting the transport of nutrients. Neuroinflammation is caused by the activation of microglia which mediate immune responses. Microglia are activated and begin producing cytokines that increase neuroinflammation. All of these factors result in mass neuronal and synaptic loss causing the cortex region of the brain to atrophy, or decrease in size.3-7
Eventually, Alzheimer’s kills, but not before It takes everything away from you.
Alzheimer’s Association
How can stem cell therapy improve the symptoms of Alzheimer’s disease?
- Human umbilical cord mesenchymal stem cells (hUC-MSCs) can promote the release of acetylcholine, promote neurogenesis and synaptic formation and can reduce oxidative stress and cell death. Research is showing hUC-MSCs to be a better alternative to allogeneic stem cells because of their hypo-immunogenicity, superior tropism, high differentiation potential and paracrine activity.10-13
- Evidence suggests HUC-MSCs can differentiate into a variety of neuro-regulatory molecules and can elevate several factors including brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF), insulin-like growth factor 1 (IGF-1), Glucagon-like pepetide-1 (GLP-1), and vascular endothelial growth factor (VEGF).9
- Neural stem cells transplanted at sites of nerve injury are thought to promote functional recovery by producing trophic factors that induce survival and regeneration of host neurons. Intravenously administered mesenchymal stem cells are also capable of crossing the blood-brain barrier and effectively migrating to regions of neural injury, without inducing tumor growth or an immune response.9
Research has shown mesenchymal stem cells have the potential to affect Alzheimer’s through multiple pathways and can:
- Decrease Amyloid-beta plaque formation
- Stimulate neurogenesis, synaptogenesis and neuronal differentiation
- Rescue spatial learning and memory deficits
- Possibly decrease inflammation by upregulating neuroprotective cytokines and decreasing pro-inflammatory cytokines
According ClinicalTrials.gov (https://clinicaltrials.gov) on March 18, 2019, the safety and efficacy results from animal models has led to the following five trials evaluating the safety and efficacy of hUC-MSC transplantation in patients diagnosed with Alzheimer’s disease.
What is the treatment protocol for Alzheimer’s disease at the Stem Cells Transplant Institute?
The Stem Cells Transplant Institute recommends the use of hUC-MSCs for the treatment of Alzheimer’s disease. For optimal results, we recommend Aggressive Platinum Therapy (APT). APT is a 4-day treatment plan.
Each day you will receive the following:
- Mesenchymal stem cells (MSC) cultured and expanded from human umbilical cord tissue.
- Antioxidant therapy with vitamin C and glutathione
- Ozone therapy
- Platelet-rich plasma therapy (PRP)
Thank you all bringing me my husband back. Most of you do
not know how difficult it is for caregiver when their spouse is
affected with Alzheimer’s . I did not till had to go through it and
i do not wish it on anyone
Charles T Adams
Customer
What Are the Benefits of Human Umbilical Cord Mesenchymal Stem Cells?
- Abundant supply containing up to 10 times more stem cells than bone marrow or adipose derived stem cells
- hUC-MSC have immunosuppressors and immunomodulatory properties that allow their use in any individual without rejection- Human Leukocyte Antigen (HLA) matching is not necessary
- Greater proliferation ability than adult autologous stem cells
They regenerate at a very rapid rate - They are young and very adaptive
- They have not been impacted by the aging process
- They have not been affected by environmental toxins
- Umbilical cord stem cells can be administered multiple times over the course of days
- Eliminates the need to collect stem cells from the patient’s fat or hip bone reducing pain and recovery time
What are the challenges?
Alzheimer’s disease destroys many different types of neurons in the brain.Successful treatment requires all the stem cells to travels to and differentiate into different types of neurons and other brain cells correctly.At this time stem cell therapy does not stop the underlying cause of Alzheimer’s disease and patient may need more than one treatment due to a declining effect over time
Title
Safety and Efficiency of Umbilical Cord-derived Mesenchymal Stem Cells (UC-MSC) in Patients With Alzheimer’s Disease
Study Results
No Results Available
Conditions
Alzheimer’s Disease
Interventions
Biological: Human Umbilical Cord Derived MSC
Title
Safety and Efficiency of Umbilical Cord-derived Mesenchymal Stem Cells (UC-MSC) in Patients With Alzheimer’s Disease
Study Results
No Results Available
Conditions
Alzheimer’s Disease
Interventions
Biological: Human Umbilical Cord Derived MSC
Title
Safety and Efficiency of Umbilical Cord-derived Mesenchymal Stem Cells (UC-MSC) in Patients With Alzheimer’s Disease
Study Results
No Results Available
Conditions
Alzheimer’s Disease
Interventions
Biological: Human Umbilical Cord Derived MSC
Title
Safety and Efficiency of Umbilical Cord-derived Mesenchymal Stem Cells (UC-MSC) in Patients With Alzheimer’s Disease
Study Results
No Results Available
Conditions
Alzheimer’s Disease
Interventions
Biological: Human Umbilical Cord Derived MSC
UMBILICAL CORD DONATIONS
How Are the Stem Cells Collected?
Our clinic focuses on obtaining healthy stem cells exclusively from umbilical cord blood donors. We collect the placenta once the baby is born, with the parent’s informed consent. Additionally, we follow strict ethical guidelines and collect stem cells from reliable and reputable sources.
INTRAVENUS ADMINISTRATION
How Are the Stem Cells Administered?
Our nursing staff administers the stem cells through an intravenous and intra-pulmonary route. For the most effective outcomes, intravenous administration is preferred.
About the Stem Cells Transplant Institute
Our clinic is located in Costa Rica, which is one of the most popular medical tourism destinations for stem cell therapy. At the Stem Cells Transplant Institute, we have a skilled team of doctors and medical professionals who collect and administer stem cells to treat autism and other conditions. Every patient receives the most cost-effective and top-notch care from our dedicated team.
Please fill this form
Scientific References:
- Fu et al. Stem cell transplantation therapy in Parkinson’s disease. SpringerPlus (2015) 4:597
- Joyce et al. Mesenchymal stem cell for the treatment of neurodegenerative disease. Regen Med. 2010, November, 5(6)933-946. Doi:10.2217/rme.10.72
- Helena Vilaça-Faria, António J. Salgado and Fábio G.
- Teixeira Mesenchymal Stem Cells-derived Exosomes: A New Possible Therapeutic Strategy for Parkinson’s disease. Cells2019, 8(2), 118; doi:3390/cells8020118
Teixeira, F.G.; Carvalho, M.M.; Neves-Carvalho, A.; Panchalingam, K.M.; Behie, L.A.; Pinto, L.; Sousa, N.; Salgado, A.J. Secretome of mesenchymal progenitors from the umbilical cord acts as modulator of neural/glial proliferation and differentiation. Stem Cell Rev.2015, 11, 288–297. [Google Scholar] [CrossRef] [PubMed] - Gao, F.; Chiu, S.M.; Motan, D.A.; Zhang, Z.; Chen, L.; Ji, H.L.; Tse, H.F.; Fu, Q.L.; Lian, Q. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis.2016, 7, e2062. [Google Scholar] [CrossRef] [PubMed]
- Joyce, N.; Annett, G.; Wirthlin, L.; Olson, S.; Bauer, G.; Nolta, J.A. Mesenchymal stem cells for the treatment of neurodegenerative disease. Med.2010, 5, 933–946. [Google Scholar] [CrossRef] [PubMed]
- Fraga, J.S.; Silva, N.A.; Lourenco, A.S.; Goncalves, V.; Neves, N.M.; Reis, R.L.; Rodrigues, A.J.; Manadas, B.; Sousa, N.; Salgado, A.J. Unveiling the effects of the secretome of mesenchymal progenitors from the umbilical cord in different neuronal cell populations. Biochimie2013, 95, 2297–2303. [Google Scholar] [CrossRef] [PubMed]
- Ribeiro, C.A.; Fraga, J.S.; Graos, M.; Neves, N.M.; Reis, R.L.; Gimble, J.M.; Sousa, N.; Salgado, A.J. The secretome of stem cells isolated from the adipose tissue and Wharton jelly acts differently on central nervous system derived cell populations. Stem Cell Res. Ther.2012, 3, 18. [Google Scholar] [CrossRef]
- Ribeiro, C.A.; Salgado, A.J.; Fraga, J.S.; Silva, N.A.; Reis, R.L.; Sousa, N. The secretome of bone marrow mesenchymal stem cells-conditioned media varies with time and drives a distinct effect on mature neurons and glial cells (primary cultures). Tissue Eng. Regen. Med.2011, 5, 668–672. [Google Scholar] [CrossRef]
- Salgado, A.J.; Fraga, J.S.; Mesquita, A.R.; Neves, N.M.; Reis, R.L.; Sousa, N. Role of human umbilical cord mesenchymal progenitors conditioned media in neuronal/glial cell densities, viability, and proliferation. Stem Cells Dev.2010, 19, 1067–1074. [Google Scholar] [CrossRef]
- Martins, L.F.; Costa, R.O.; Pedro, J.R.; Aguiar, P.; Serra, S.C.; Teixeira, F.G.; Sousa, N.; Salgado, A.J.; Almeida, R.D. Mesenchymal stem cells secretome-induced axonal outgrowth is mediated by BDNF. Rep.2017, 7, 4153. [Google Scholar] [CrossRef]
- Serra, S.C.; Costa, J.C.; Assuncao-Silva, R.C.; Teixeira, F.G.; Silva, N.A.; Anjo, S.I.; Manadas, B.; Gimble, J.M.; Behie, L.A.; Salgado, A.J. Influence of passage number on the impact of the secretome of adipose tissue stem cells on neural survival, neurodifferentiation and axonal growth. Biochimie2018, 155, 119–128. [Google Scholar] [CrossRef]
- Assuncao-Silva, R.C.; Mendes-Pinheiro, B.; Patricio, P.; Behie, L.A.; Teixeira, F.G.; Pinto, L.; Salgado, A.J. Exploiting the impact of the secretome of MSCs isolated from different tissue sources on neuronal differentiation and axonal growth. Biochimie2018, 155, 83–91. [Google Scholar] [CrossRef] [PubMed]
